Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Reappraisal of the genetic diversity and pharmacogenetic assessment of CES1

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Novel Genetic Causes of Gastrointestinal Polyposis Syndromes

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Challenges in conducting paediatric trials with off-patent drugs

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The CES1 gene encodes a hydrolase that metabolizes important drugs. Variants generated by exchange of segments with CES1P1 complicate genotyping of CES1. Using a highly specific procedure we examined DNA samples from 200 Caucasians and identified 46 single nucleotide variants (SNVs) in CES1 and 21 SNVs in CES1A2, a hybrid composed of CES1 and CES1P1. Several of these SNVs were novel. The frequencies of SNVs with a potential functional impact were below 0.02 suggesting limited pharmacogenetic potential for CES1 genotyping. In silico PCR revealed that the majority of the primer pairs for amplification of CES1 or CES1A2 in three previous studies lacked specificity, which partially explains a limited overlap with our findings.

OriginalsprogEngelsk
TidsskriftPharmacogenomics
Vol/bind18
Udgave nummer13
Sider (fra-til)1241-1257
Antal sider17
ISSN1462-2416
DOI
StatusUdgivet - aug. 2017

ID: 51638560